SCHEMBL24019673

SCHEMBL24019673

CCNC(=O)CN1CCC(c2ccccc2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.54
▸ DRD2 P14416 4/20 0.53
▸ DRD4 P21917 2/20 0.53
▸ DRD3 P35462 2/20 0.53
▸ GAA P10253 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ LMNA P02545 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ PRCP P42785 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ STAT1 P42224 1/20 0.48
▸ SLC18A3 Q16572 3/20 0.48
▸ SIGMAR1 Q99720 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ DRD1 P21728 1/20 0.47
▸ DRD5 P21918 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24112340 0.86 DRD2 (0.55) HTTDRD2DRD4DRD3GAA
SCHEMBL24450334 0.82 HTT (0.73) HTTDRD2DRD4DRD3GAA
SCHEMBL12209849 0.81 ALDH1A1 (0.60) HTTDRD2GAAALDH1A1LMNA
SCHEMBL26238905 0.78 PRCP (0.58) HTTDRD2DRD4DRD3PRCP
SCHEMBL14207950 0.78 DRD2 (0.63) HTTDRD2DRD4DRD3PRCP
SCHEMBL24652524 0.78 ALDH1A1 (0.57) DRD2GAAALDH1A1LMNAKMT2A
SCHEMBL3165125 0.78 ALDH1A1 (0.57) DRD2GAAALDH1A1LMNAKMT2A
SCHEMBL22307922 0.75 DRD2 (0.66) DRD2DRD4DRD3GAAALDH1A1
SCHEMBL23374660 0.75 DRD2 (0.66) DRD2DRD4DRD3GAAALDH1A1
SCHEMBL9912160 0.75 DRD2 (0.66) DRD2DRD4DRD3GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402896-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2022-12-22 — — US disclosed
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-12-13 — — US disclosed
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2021-11-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402896-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTSV, CTRL, CTSL HTT 2625/4885DRD2 4607/4885DRD4 4749/4885
US-11174231-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL HTT 1484/4885DRD2 4365/4885DRD4 4463/4885
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL HTT 1484/4885DRD2 4365/4885DRD4 4463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback